Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | Using AI to predict light chain amyloidosis in patients with MGUS and SMM

Eli Muchtar • 6 Sep 2022
ISA 2022
Amyloidosis Rare Diseases Smoldering Myeloma

Eli Muchtar, MD, Mayo Clinic, Rochester, MN, comments on the potential of artificial intelligence (AI) in predicting the risk of developing AL amyloidosis in patients with multiple myeloma precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

More from Eli Muchtar

1:43
Feasibility of double autologous stem cell transplantation in patients with AL amyloidosis
Eli Muchtar • 6 Sep 2022
1:02
Incidence of hypovitaminosis D in patients with renal AL amyloidosis
Eli Muchtar • 6 Sep 2022
6:10
Auto-HSCT in AL amyloidosis
Eli Muchtar • 9 Sep 2020
4:51
Localized amyloidosis: symptoms and site of disease
Eli Muchtar • 9 Sep 2020

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals